Cytek Biosciences, Inc. (CTKB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Cytek Biosciences is a cell analysis solutions company leveraging Full Spectrum Profiling (FSP) technology. The company operates as a single reportable segment, manufacturing instruments (e.g., Aurora, Northern Lights) and providing reagents and services globally. The company is currently transitioning manufacturing operations from Seattle, Washington, to Singapore to optimize costs.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $87,059 |
| Gross Profit | $44,024 |
| Gross Margin | 51% |
| Net Loss | $(16,985) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) |
| Cash and Cash Equivalents | $75,470 |
| Marketable Securities | $186,552 |
| Total Liquidity (Cash + Securities) | $262,022 |
| Long-Term Debt | $791 |
| Operating Cash Flow | $(17) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5% year-over-year (YoY) to $87.1 million for the six months ended June 30, 2025, compared to $91.5 million in the prior year. Product revenue fell 13% to $59.5 million, while service revenue grew 21% to $27.5 million.
- Margin Compression: Gross margin declined from 53% in the prior year to 51%, driven by lower product revenue reducing fixed cost absorption and higher service material costs.
- Operating Expenses: General and Administrative (G&A) expenses increased 14% YoY to $26.4 million, primarily due to ongoing patent litigation costs. Research and Development (R&D) expenses decreased 6% to $18.6 million due to lower headcount and engineering costs.
- Share Repurchases: The company repurchased 3.3 million shares for approximately $15.1 million during the six-month period. As of June 30, 2025, $35.0 million remains available under the current repurchase program.
- Legal Settlement Liability: The total liability related to the Becton, Dickinson and Company (BD) settlement stands at $10.4 million.
Guidance, Outlook, and Risks
- Outlook: Management expects expenses to increase substantially in the future to support R&D, commercial infrastructure, and geographic expansion. The company anticipates that service revenue will become an increasingly important contributor as the installed base grows.
- Internal Control Weaknesses: The company identified material weaknesses in its internal control over financial reporting related to the control environment, general IT controls (access security and change management), and journal entry review procedures. Management is actively remediating these issues.
- Legal Proceedings: Beckman Coulter, Inc. has sued Cytek alleging patent infringement regarding flow cytometer products. A trial is scheduled for August 2026. The company intends to vigorously defend itself.
- Regulatory and Trade Risks: New U.S. export controls announced in January 2025 impact the export of high-parameter flow cytometers to certain countries, including China. Additionally, the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 restores immediate deductions for domestic R&D, which the company is evaluating for impact on deferred tax assets.
Investor Verification Checklist
- Internal Controls: Verify the progress of remediation plans for the identified material weaknesses in internal controls over financial reporting.
- Litigation Exposure: Monitor the status of the Beckman Coulter patent infringement lawsuit and potential financial impact.
- Export Compliance: Assess the impact of new U.S. export controls on sales to China and other restricted jurisdictions.
- Manufacturing Transition: Track the timeline and cost implications of moving manufacturing operations from Seattle to Singapore.
- Revenue Mix: Evaluate the sustainability of service revenue growth versus the decline in product sales, particularly in the EMEA and U.S. academic sectors.